Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The article contains both the theory in terms of the partition coefficient of a compound, and application to the separation of amino acids on a water-impregnated silica column eluted with a water:chloroform:n-butanol mixture.
== Active site == The spherical carboxypeptidase domain of the catalytic subunit has a circular indentation in the surface which is the location of the active-site groove. The base of the groove is formed by 3 β-sheets while the walls of the groove are lined with α-helices. The electron density in the middle of the groove allows a space for the zinc ion cofactor to bind. The P1' residue of the substrate is placed in a specific cavity (S1') of the active-site groove while the P1 residues and on extend into a mostly hydrophobic area of the groove (in pockets S1, S2, etc.). The scissile peptide bond is held in place with several polar interactions between protein side groups. The nitrogen atom on the C-terminal side is anchored to the nearby guanidine groups of arginine molecules. On the N-terminal side, the nitrogen atom is held by hydrogen bonds with tyrosine while the carbonyl group is held by hydrogen bonds with lysine. These interactions stretch the peptide bond and set it up for the water molecule to break it apart. While there are technically two active sites on the tetramer, one on each active subunit, only one active site can be used at a time.
=== Pharmacodynamics === Nor-LSD showed 5- to 29-fold lower affinity for the serotonin 5-HT2 receptor compared to LSD (Ki = 30–158 nM vs. 5.4 nM, respectively). It also showed affinity for the serotonin 5-HT1 receptor. In another more recent study however, nor-LSD showed similar or even higher affinities, activational potencies, and/or efficacies at the serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors as LSD, whereas it showed 36-fold lower affinity for the serotonin 5-HT2C receptor compared to LSD. Nor-LSD failed to completely substitute for LSD in rodent drug discrimination tests even at very high doses. The greatest degree of substitution with nor-LSD was 75% at a dose of 7,420 nM/kg, whereas 100% substitution occurred with LSD at a dose of 186 nM/kg (a 40-fold lower dose). The ED50Tooltip median effective dose was 2,594 nM/kg for nor-LSD and 46 nM/kg for LSD. Hence, nor-LSD was approximately 56-fold less potent than LSD in terms of producing LSD-like effects in rodents and failed to produce full LSD-like effects even at the highest assessed dose. In another study, nor-LSD failed to produce LSD-like electroencephalogram (EEG) changes in rabbits.
== Contraindications == Like other dihydropyridines, lercanidipine is contraindicated in unstable angina pectoris, uncontrolled cardiac failure, shortly after a myocardial infarction, and in patients with left ventricular outflow tract obstruction. It is also contraindicated during pregnancy and in women who may become pregnant, because data regarding safety for the unborn are lacking, as well as in patients with severe liver and renal impairment. The drug must not be combined with strong inhibitors of the liver enzyme CYP3A4 or with the immunosuppressant drug ciclosporin.
In two minor league seasons from 1989 to 1990, he had managed six home runs in 932 at bats–a ratio of 155 at bats per home run (AB/HR). With 15 home runs in his first year in Houston, that average shrunk to 36.9. He also exhibited extraordinary plate discipline for a rookie: while ranking tenth in the league in walks with 75, his OBP placed fifth at .387. Of the power surge, commented Bagwell to hitting coach Rudy Jaramillo, "That's awesome", to which he reacted, "Awesome? We can get more out of you than that." By altering an approach to contact the pitch with topspin as he did when he arriving to Houston, Jaramillo taught Bagwell to hit with backspin, resulting in a soaring trajectory rather than nose diving. He also habituated Bagwell to manipulate the count, waiting for a pitch to drive instead of indiscriminately swinging at any pitch that appeared to be a strike. Accounted Bagwell of the newfound advantage, "I didn't hit many home runs in the minor leagues, but when I hit one, when I got backspin on it, it went a long way." Although firmly established as the Astros' first baseman from Opening Day in 1991, Bagwell remarked years later that transitioning from third base was not automatic. First basemen approach fielding plays from their right side, which is opposite to playing third base. He recounted one conversation that occurred during an Astros pitching change in a game against St. Louis. Shortstop Ozzie Smith was on first and asked Bagwell, "How's it going?" Bagwell responded, "I'm really struggling with my backhand." Smith replied, "Well, here's what you do.
Sources: en.wikipedia.org
Eric Carlin, a member of the ACMD and former chairman of the English Drug Education Forum, also resigned after the announcement. He said the decision by the Home Secretary was "unduly based on media and political pressure" and there was "little or no discussion about how our recommendation to classify this drug would be likely to impact on young people's behaviour." Some former members of the ACMD and various charity groups expressed concern over the banning of the drug, arguing it would inevitably criminalise users, particularly young people. Others expressed concern that the drug would be left in the hands of black market dealers, who will only compound the problem. Carlin's resignation was specifically linked to the criminalisation of mephedrone; he stated: "We need to review our entire approach to drugs, dumping the idea that legally-sanctioned punishments for drug users should constitute a main part of the armoury in helping to solve our country's drug problems. We need to stop harming people who need help and support". The parliamentary debate was held on 8 April, one day after the 2010 general election had been announced, meaning it was during the so-called "wash-up period" when legislation is passed with little scrutiny. Only one hour was spent debating the ban, and all three parties agreed, meaning no vote was required.
== Applications == Although protactinium is situated in the periodic table between uranium and thorium, both of which have numerous applications, there are currently no uses for protactinium outside scientific research owing to its scarcity, high radioactivity, and high toxicity. 231Pa arises naturally from the decay of natural 235U, and artificially in nuclear reactors by the reaction 232Th + n → 231Th + 2n and the subsequent beta decay of 231Th. It was once thought to be able to support a nuclear chain reaction, which could in principle be used to build nuclear weapons; the physicist Walter Seifritz once estimated the associated critical mass as 750±180 kg. However, the possibility of criticality of 231Pa has since been ruled out. With the advent of highly sensitive mass spectrometers, an application of 231Pa as a tracer in geology and paleoceanography has become possible. In this application, the ratio of 231Pa to 230Th is used for radiometric dating of sediments which are up to 175,000 years old, and in modeling of the formation of minerals. In particular, its evaluation in oceanic sediments helped to reconstruct the movements of North Atlantic water bodies during the last melting of Ice Age glaciers. Some of the protactinium-related dating variations rely on analysis of the relative concentrations of several long-living members of the uranium decay chain – uranium, protactinium, and thorium, for example. These elements have 6, 5, and 4 valence electrons, thus favoring +6, +5, and +4 oxidation states respectively, and display different physical and chemical properties.
== History == They were first characterized in 1907 by Siegfried Oberndorfer, a German pathologist at LMU Munich, who coined the term karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. The recognition of their endocrine-related properties was later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut. Some sources credit Otto Lubarsch with the discovery.
=== Andy: Get The Poison Out === First aired: 4 November 2010 Meet Andy, the self-appointed king of Fresno. He is an obnoxious bully who makes life miserable for his victims, Steven and Taylor. He also makes the biggest mistake of calling out Mayhem, so Mayhem brings out "the greatest fighter he has ever known" to take care of Andy. That fighter turns out to be Mayhem himself. After easily being tapped out 5 times in the first round and knocked out in the second round, Steven and Taylor won $10,000. After the fight, Mayhem tells a humbled Andy that he had to deal with bullies most of his life and implores him to change his ways because he eventually will come across someone that is bigger, badder and meaner than Andy himself.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.